APVO vs. ADTX, SXTC, CMRA, HSTO, BLPH, ATHX, AMPE, EVFM, OBSV, and SPRC
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Aditxt (ADTX), China SXT Pharmaceuticals (SXTC), Comera Life Sciences (CMRA), Histogen (HSTO), Bellerophon Therapeutics (BLPH), Athersys (ATHX), Ampio Pharmaceuticals (AMPE), Evofem Biosciences (EVFM), ObsEva (OBSV), and SciSparc (SPRC). These companies are all part of the "pharmaceutical preparations" industry.
Aptevo Therapeutics (NASDAQ:APVO) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, institutional ownership, valuation, media sentiment, community ranking, analyst recommendations, risk, profitability and earnings.
In the previous week, Aptevo Therapeutics had 2 more articles in the media than Aditxt. MarketBeat recorded 5 mentions for Aptevo Therapeutics and 3 mentions for Aditxt. Aditxt's average media sentiment score of 0.33 beat Aptevo Therapeutics' score of -0.39 indicating that Aditxt is being referred to more favorably in the news media.
8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 0.3% of Aptevo Therapeutics shares are owned by insiders. Comparatively, 1.2% of Aditxt shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Aptevo Therapeutics has higher revenue and earnings than Aditxt.
Aptevo Therapeutics has a net margin of 0.00% compared to Aditxt's net margin of -5,016.31%. Aptevo Therapeutics' return on equity of -221.61% beat Aditxt's return on equity.
Aptevo Therapeutics has a beta of 5.13, meaning that its stock price is 413% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.35, meaning that its stock price is 35% more volatile than the S&P 500.
Aditxt has a consensus price target of $61.00, indicating a potential upside of 2,934.83%. Given Aditxt's higher probable upside, analysts plainly believe Aditxt is more favorable than Aptevo Therapeutics.
Aptevo Therapeutics received 194 more outperform votes than Aditxt when rated by MarketBeat users. Likewise, 52.66% of users gave Aptevo Therapeutics an outperform vote while only 44.44% of users gave Aditxt an outperform vote.
Summary
Aptevo Therapeutics beats Aditxt on 10 of the 14 factors compared between the two stocks.
Get Aptevo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aptevo Therapeutics Competitors List
Related Companies and Tools